Skip to main content

Casdin Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

95
Companies
$8.1B
Total invested
$93.1M
Avg. check
22
Industries
Biotechnology 20Health Care 16Therapeutics 10Medical 7Life Science 5Biopharma 4+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 95
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post-IPO Equity
Apella Technology
January 2026

Apella Technology is an AI startup that brings modern engineering to improve surgery.

Artificial Intelligence (AI) · Oakland$80.0M Series B
Voyager Therapeutics
January 2024

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Biotechnology · Cambridge$100.0M Post-IPO Equity
Amplo Biotechnology
January 2025

Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.

Biotechnology · La Jolla$2.9M Grant
Exai Bio
December 2021

Exai Bio is an orphan non-coding RNAs and AI-based liquid biopsy company.

Biotechnology · Palo Alto$67.5M Series A
Vector Biomed
December 2022

Vector Biomed is a state-of-the-art custom vector design and GMP manufacturing company.

Machinery Manufacturing · Gaithersburg$15.0M Venture - Series Unknown
Exscientia
December 2023

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

Artificial Intelligence (AI) · Oxford$2.3M Grant
ONI
December 2021

ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.

Biotechnology · Oxford$75.0M Series B
Xcell Biosciences
December 2024

Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.

Biotechnology · San Francisco$1.4M Undisclosed
Depixus
December 2021

Depixus are pioneering the development of MAGNA, a novel genetic analysis technology for decoding the dynamic genome.

Biotechnology · Courbevoie$34.5M Series A
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post-IPO Equity
Variant Bio
November 2021

Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.

Biotechnology · Seattle$105.0M Series B
Umoja Biopharma
January 2025

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

Biopharma · Seattle$100.0M Series C
Exo Therapeutics
October 2021

Exo Therapeutics is a small molecule drug discovery and development company.

Biotechnology · Cambridge$78.0M Series B
Cedilla Therapeutics
October 2021

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

Biotechnology · Cambridge$25.0M Series B
Loop Medical
October 2021

Loop Medical develops an easy and painless blood collection technology making it accessible to all.

Health Care · Lausanne$6.4M Series A
Hexagon Bio
October 2022

Hexagon Bio is a data-driven biotech company developing targeted small molecule therapeutics.

Biotechnology · Menlo Park$77.3M Series B
4D Molecular Therapeutics
November 2025

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$100.0M Post Ipo Equity
Octave
October 2025

Octave is a precision care company that provides diagnostic tools and care solutions for neurodegenerative diseases.

Biotechnology · Menlo ParkGrant
CANbridge Pharmaceuticals
August 2025

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

Biotechnology · Beijing$12.7M Post Ipo Equity
BBOT
August 2025

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

Biopharma · Palo Alto$261.0M Post Ipo Equity
Absci
July 2025

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI) · Vancouver$50.0M Post Ipo Equity
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonSeries Unknown
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant

Where Casdin Capital invests

Biotechnology20
Health Care16
Therapeutics10
Medical7
Life Science5
Biopharma4

About Casdin Capital's portfolio

How many companies has Casdin Capital invested in?

Casdin Capital has invested in 95 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Casdin Capital invest in?

Casdin Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 22 different industry categories.

What is Casdin Capital's largest investment?

Among tracked funding rounds, BBOT received $261.0M in a Post Ipo Equity round. Casdin Capital's total known invested capital is $8.1B.

What is the average investment size for Casdin Capital?

Casdin Capital's average investment size is $93.1M across its portfolio of 95 companies.

What are Casdin Capital's most recent investments?

Recent Casdin Capital portfolio additions include Foghorn Therapeutics, Apella Technology, Voyager Therapeutics, Amplo Biotechnology, Exai Bio. These companies were founded in 2020 or later.

Reach the founders behind these 95 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →